SSY GROUP - VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT

VOLUNTARY ANNOUNCEMENT

UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approvals for drug production and registration for Ozagrel Sodium Injection (5ml: 40mg and 2.5ml: 20mg) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation.

Ozagrel Sodium Injection is mainly used for treatment of acute thrombotic cerebral infarction and motor dysfunction associated with cerebral infarction. The Group already has two intravenous infusion solution ("IV") specifications of Ozagrel Sodium Chloride Injection (250ml:80mg and 100ml:80mg) approved for market. This approval achieves our full dosage form coverage in ozagrel sodium "small-volume injection + sodium chloride IV", which helps the Group further expand its neurology market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 25 August 2026